Amgen shelves early-stage bispecific T cell engager
Amgen has stopped development of a Phase 1 bispecific T cell engager, a type of medicine that is core to its oncology portfolio and for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
